EPISODE · Sep 2, 2026 · 12 MIN
Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
from BiotechTV - News · host BiotechTV
CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines.
Embed this episode
Ready to play
Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.